| Autor: |
Ahmadpour ST; Nutrition, Croissance et Cancer, Inserm, UMR1069, Université de Tours, 37032 Tours, France., Orre C; Inserm U1083, UMR CNRS 6214, Angers University, 49933 Angers, France., Bertevello PS; Nutrition, Croissance et Cancer, Inserm, UMR1069, Université de Tours, 37032 Tours, France., Mirebeau-Prunier D; Inserm U1083, UMR CNRS 6214, Angers University, 49933 Angers, France., Dumas JF; Nutrition, Croissance et Cancer, Inserm, UMR1069, Université de Tours, 37032 Tours, France., Desquiret-Dumas V; Inserm U1083, UMR CNRS 6214, Angers University, 49933 Angers, France. |
| Abstrakt: |
Long noncoding RNAs (lncRNAs) are a subclass of noncoding RNAs composed of more than 200 nucleotides without the ability to encode functional proteins. Given their involvement in critical cellular processes such as gene expression regulation, transcription, and translation, lncRNAs play a significant role in organism homeostasis. Breast cancer (BC) is the second most common cancer worldwide and evidence has shown a relationship between aberrant lncRNA expression and BC development. One of the main obstacles in BC control is multidrug chemoresistance, which is associated with the deregulation of multiple mechanisms such as efflux transporter activity, mitochondrial metabolism reprogramming, and epigenetic regulation as well as apoptosis and autophagy. Studies have shown the involvement of a large number of lncRNAs in the regulation of such pathways. However, the underlying mechanism is not clearly elucidated. In this review, we present the principal mechanisms associated with BC chemoresistance that can be directly or indirectly regulated by lncRNA, highlighting the importance of lncRNA in controlling BC chemoresistance. Understanding these mechanisms in deep detail may interest the clinical outcome of BC patients and could be used as therapeutic targets to overcome BC therapy resistance. |
